Transcode Therapeutics Inc (RNAZ)

US · Healthcare · Biotechnology

$1.72+2.38%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-6.7M

EPS

$-7.17

Market cap

$1.8M

Forward P/E

0.0

P/B

2.83

Book value

$-27.38

EPS (TTM)

$-48.28

52-week high

$20.99

52-week low

$1.63

50-day MA

$4.82

200-day MA

$7.29

Beta

1.17

Analysts rate Transcode Therapeutics Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $10.00.

Insiders

1.78%

Institutions

0.44%

Fund	Stake
Yorkville Advisors Global, LP	0.12%
Geode Capital Management, LLC	0.08%
UBS Group AG	0.05%
Vanguard Capital Management, LLC	0.04%
Vanguard Fiduciary Trust Co	0.02%
Mercer Global Advisors Inc.	0.01%
Tower Research Capital LLC	0.00%
Wells Fargo & Co	0.00%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Transcode Therapeutics Inc — free to start.

Data updated 2026-09-18.